Modern hiv-1 treatment is far simpler than it was twenty years ago, but the details still matter. This guide adds the practical parts the article below leaves out: which genetic tests genuinely change prescribing, which do not, and what to ask your care team at the next visit.
On this page
HIV-1 (Human Immunodeficiency Virus type 1) positions a worldwide health concern and requires tailored treatment approaches. Over time, there have been notable innovations in addressing HIV-1, resulting in better overall well-being and extended lifespan for affected individuals. While antiretroviral therapy (ART) remains central to HIV-1 treatment, determining the appropriate treatment can be challenging due to the varying individual reactions to medication. This is where pharmacogenetic testing can add one piece of the picture, alongside resistance testing of the virus and the day to day work of staying on treatment.
Treatment of HIV-1: An Overview
As a result of HIV-1, the immune system is attacked, specifically CD4 cells (T cells), which play an important role in immune defense – information source Rockefeller University Press. Without effective treatment, the virus weakens the immune system, resulting in acquired immune deficiency syndrome (AIDS). By suppressing the virus, ART helps the immune system recover and function normally. There are several classes of ART drugs (Information source NIH):
- NRTIs (Nucleoside Reverse Transcriptase Inhibitors)
- NNRTIs (non-nucleoside reverse transcriptase inhibitors)
- Protease inhibitors (PIs)
- integrase strand transfer inhibitor (INSTIs)
- Fusion Inhibitors (FIs)
Drug interactions, side effects, and the development of drug-resistant strains of HIV-1 add to the complexity of treatment, even with highly effective ART.
HIV-1 Treatment Enhancement by PGx Testing
Genetics has a real but narrow part in HIV-1 treatment, and it helps to know where that part starts and stops.
The one genetic test that gates an HIV prescription
Before abacavir is prescribed, guidelines call for testing for the HLA-B*57:01 variant. People who carry it can have a serious hypersensitivity reaction, so a positive result means abacavir is not used at all. This is a standalone test ordered through the HIV clinic. HLA-B is not part of the RPh Labs 20-gene panel.
Genes that affect how an antiretroviral is cleared
Efavirenz is broken down mainly by CYP2B6, and people who carry two reduced function copies reach higher drug levels, which tracks with more central nervous system side effects. CYP2B6 is on the RPh Labs panel, so a report can describe that status. It is context for a prescriber, never a reason to change a dose on your own.
Keeping drug interactions to a minimum
People living with HIV-1 often take medicines for other conditions too. Most antiretroviral interactions are chemical rather than genetic: boosters such as ritonavir and cobicistat block CYP3A4 and push up the levels of other drugs. Where genes do help is on the other side of that list, with medicines such as statins, clopidogrel and some antidepressants, where gene based dosing guidance genuinely exists. Bring your full list, including supplements, to your pharmacist.
What PGx testing cannot tell you
It cannot predict whether your viral load will become undetectable, and it does not choose your regimen. That depends on which drugs you take, whether the virus carries resistance mutations, which is answered by a resistance test on the virus rather than on your DNA, and on taking the medicine every day.
What modern hiv-1 treatment looks like
For most people starting today, hiv-1 treatment means one tablet a day that contains two or three antiretroviral drugs. The goal is to lower the amount of virus in the blood until routine lab tests can no longer detect it, then keep it there for life.
Most first regimens are built around an integrase strand transfer inhibitor combined with two nucleoside reverse transcriptase inhibitors. These combinations are generally well tolerated and carry few food or timing rules, which is part of why guidelines favor them.
The article above lists the drug classes. What it does not cover is how a prescriber narrows those classes down to one prescription for you. In practice the decision turns on a short list of very practical questions.
- Your kidney and liver function, and any bone or heart history.
- Every other medicine and supplement you take, including over-the-counter products.
- Whether you are pregnant, breastfeeding or planning a pregnancy.
- Results of a resistance test on your own virus.
- Whether a specific drug requires a genetic test first, as abacavir does.
- How the regimen fits your routine, work and travel.
None of this is a decision to make alone, and none of it is fixed forever. Antiretroviral therapy can be changed later for side effects, pregnancy, new medicines or simply a simpler schedule, always with your prescriber.
Efavirenz side effects and the CYP2B6 gene
Efavirenz is the antiretroviral with the clearest published gene link. It is broken down mainly by the liver enzyme CYP2B6, and common variants in that gene slow the process considerably.
People who carry two reduced function copies clear the drug slowly, so blood levels run higher than average. Higher levels are associated with the central nervous system efavirenz side effects people notice most: dizziness, vivid dreams, poor sleep and daytime grogginess.
That association is strong enough to be published. CPIC maintains a guideline for efavirenz and CYP2B6, and the FDA table of pharmacogenetic associations lists the pair as well. When a genotype predicts slow metabolism, a prescriber may consider a lower dose or a different drug.
What a CYP2B6 result does not tell you
It does not tell you whether efavirenz will suppress your virus, and it does not replace resistance testing. It also does not make efavirenz side effects certain or impossible; it describes risk, not destiny.
CYP2B6 is one of the 20 genes on the RPh Labs panel, so this result is available if your prescriber wants it. Many people starting hiv-1 treatment in 2026 are never offered efavirenz at all, in which case the result simply sits in the report for future reference.
Abacavir hypersensitivity and the HLA-B*57:01 test
Abacavir is a nucleoside reverse transcriptase inhibitor found in several combination tablets. A minority of people carry a tissue type called HLA-B*57:01, and in those people abacavir can trigger a serious immune reaction known as abacavir hypersensitivity.
The reaction usually begins within the first six weeks. It often involves several things at once: fever, rash, stomach upset, aching, cough or shortness of breath. It worsens with each dose and can be life threatening if the drug is restarted after being stopped.
Because of that, testing for HLA-B*57:01 is expected before anyone begins abacavir. A positive result means abacavir is not used, and the drug label carries a boxed warning about abacavir hypersensitivity.
This test is not part of the RPh Labs panel. HLA-B is not one of the 20 genes we report, so a pharmacogenomic panel does not replace it. Your clinician orders HLA-B*57:01 separately, usually alongside your other HIV bloodwork, and it should be done before the first dose rather than after a reaction.
If you have ever been told you are HLA-B*57:01 positive, or that you reacted to abacavir in the past, keep that on your medication list and tell every new prescriber and pharmacist. Abacavir hypersensitivity is one of the few allergy labels that should never be quietly dropped from a chart.
What an undetectable viral load actually means
A viral load test counts copies of virus in a sample of blood. An undetectable viral load means the number has fallen below the level that particular test can measure. It does not mean zero, and it does not mean the virus is gone from the body.
It does mean two important things. Your immune system gets room to recover, and once an undetectable viral load has been sustained on treatment, HIV is not passed on to sexual partners. That is the finding behind the phrase undetectable equals untransmittable.
It is not a cure. If antiretroviral therapy stops, the virus usually rebounds within weeks. This is why nobody should pause or stop hiv-1 treatment on their own, even when they feel completely well and lab results look perfect.
Undetectable does not mean you have to accept side effects
An undetectable viral load says the regimen is working against the virus. It says nothing about how you feel on it. If a medicine gives you nausea, insomnia, headaches or mood changes, that is worth raising, because there is usually more than one combination that will hold the virus down.
Hiv drug interactions worth raising with your pharmacist
Antiretrovirals rarely sit alone. Most people take something else at some point, and hiv drug interactions are one of the most common practical problems in HIV care. They are also one of the easiest to catch early.
These are the patterns a pharmacist checks for most often:
- Antacids, calcium, iron and magnesium supplements can bind some integrase inhibitors in the gut and lower absorption, so timing matters.
- Acid reducing drugs change how well certain antiretrovirals dissolve and absorb.
- Boosting agents such as ritonavir and cobicistat deliberately slow liver enzymes, which can raise levels of statins, inhaled or injected steroids, and some sedatives.
- Rifampin and a few anti-seizure drugs speed those enzymes up and can drop antiretroviral levels far enough to matter.
- St John’s wort is a common supplement that lowers levels of several antiretrovirals.
The simplest defense is a single up-to-date list of everything you take, including supplements and anything bought without a prescription, shown at every appointment and every pharmacy. Our medication list by gene is a useful starting point for the pharmacogenomic side of that conversation.
One honest limit: hiv drug interactions are chemistry between drugs, not genetics. A gene result cannot replace an interaction check. The two do overlap, though, because a strong inhibitor can make a normal metabolizer behave like a poor one for as long as it is taken.
Staying on antiretroviral therapy day to day
Nothing about antiretroviral therapy works without consistency. Taking it most days is not the same as taking it every day, because gaps give the virus room to replicate and to develop resistance to the drugs you are using.
Practical habits that help:
- Tie the dose to something you already do without thinking, such as brushing your teeth or making coffee.
- Set a repeating phone alarm and keep it set even after the habit forms.
- Refill a week early rather than on the last pill, and ask about 90-day supplies if your plan allows them.
- Pack extra doses in carry-on luggage, never in checked bags.
- Ask your pharmacy to flag any change in pill appearance so a generic switch does not worry you.
If you miss a dose, ask your prescriber or pharmacist what to do rather than doubling up on your own. The right answer depends on which regimen you take and how much time has passed.
Early side effects often settle within the first few weeks. If they do not, say so rather than stopping. Quietly abandoning a regimen is riskier than switching to a different one under supervision.
Where pgx testing fits into hiv-1 treatment, and where it does not
This is where the article above goes further than the evidence. Pharmacogenomic testing does not pick your antiretroviral regimen, and it does not predict how well the virus will be suppressed. Most modern antiretrovirals have no gene-guided dosing at all.
Two genetic tests genuinely change HIV prescribing today, and only one of them is a pharmacogenomic panel gene:
- HLA-B*57:01 before abacavir, to prevent abacavir hypersensitivity. Ordered separately by your clinician, not on our panel.
- CYP2B6 for efavirenz dosing, which is on the RPh Labs panel and covered by a CPIC guideline.
For widely used drugs such as dolutegravir, bictegravir, tenofovir and emtricitabine, there is no routine genetic test that changes the dose. Saying otherwise sets people up to expect something a report cannot deliver.
Where a panel earns its place is the rest of the medicine cabinet. People living with HIV get depression, high cholesterol, reflux, pain and heart disease like everyone else, and those drug classes are where gene-guided prescribing is best established. Our introduction to PGx testing and the CPIC guidelines overview explain how that works.
One more limit worth stating plainly: a pharmacogenomic test does not diagnose any disease, does not test for HIV, and cannot predict whether someone’s health will change over time. It reports how your body is likely to process certain medicines. The at-home cheek swab kit exists for that narrow job and nothing more.
Questions to bring to your hiv-1 treatment visit
Appointments are short. Writing questions down ahead of time is the single easiest way to get more out of them.
- Which regimen am I on, and why this one for me?
- Has HLA-B*57:01 been checked, and does my regimen contain abacavir?
- Are any of my other medicines or supplements a problem with this regimen?
- What should I do if I miss a dose or run out while traveling?
- When is my next viral load and CD4 check, and how will I get the results?
- If a side effect does not settle, what would we try instead?
Bring your full medicine list to that visit, including anything from another prescriber. A pharmacist is often the fastest person to screen it for hiv drug interactions, and most pharmacies will do that without an appointment.
If you and your prescriber decide a pharmacogenomic report would help with your non-HIV medicines, our how it works page explains the cheek swab process and the pharmacist consultation that comes with every report.
Conclusion
The management of HIV-1 has advanced greatly, however finding the appropriate antiretroviral therapy remains an obstacle. Genetics helps in specific places: the HLA-B*57:01 test that must come before abacavir, and metabolism genes such as CYP2B6 that shape how much of a drug you are exposed to. It does not replace resistance testing, viral load monitoring or a conversation about the medicines you take for everything else.
If you are living with HIV-1 or involved in its management, your HIV clinician and pharmacist are the right people to ask about where testing fits. We hope you find it useful.
Please note that this blog is intended only for informational purposes. Always consult a doctor before taking any medical action.
Hiv-1 treatment and genetic testing FAQ
Do I need an HLA-B*57:01 test before starting any HIV medicine?
Only before abacavir, which appears in several combination tablets. The test exists to prevent abacavir hypersensitivity, a reaction that can be severe. Ask whether it has already been done, because a positive result rules abacavir out permanently and should stay on your record.
How soon do efavirenz side effects usually show up?
Central nervous system effects such as dizziness, vivid dreams and trouble sleeping typically appear in the first days to weeks and often ease over the first month. Tell your prescriber if they do not settle, and never stop the medicine on your own while you wait.
Which hiv drug interactions involve over-the-counter products?
Antacids and calcium, iron or magnesium supplements can reduce absorption of some integrase inhibitors depending on timing. St John’s wort can lower antiretroviral levels. Acid reducers matter for certain drugs. Show your pharmacist everything you take, not only prescriptions.
Does RPh Labs test for HIV?
No. We do not test for HIV or any other infection, and a pharmacogenomic report cannot diagnose disease. Our panel of 20 genes reports how your body is likely to process medicines across 240 or more drugs, which your prescriber uses alongside your other results.
Leave a Reply